Kyverna Therapeutics, Inc. KYTX Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Kyverna Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: Kyverna Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kyverna Therapeutics, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kyverna Therapeutics, Inc.'s operating cash flow?
- Kyverna Therapeutics, Inc. (KYTX) reported operating cash flow of -$41.6M in Q1 2026.
- How has Kyverna Therapeutics, Inc.'s operating cash flow changed year-over-year?
- Kyverna Therapeutics, Inc.'s operating cash flow increased by 7.4% year-over-year, from -$44.92M to -$41.6M.
- What is the long-term trend for Kyverna Therapeutics, Inc.'s operating cash flow?
- Over 2 years (2023 to 2025), Kyverna Therapeutics, Inc.'s operating cash flow has grown at a 71.3% compound annual growth rate (CAGR), from -$52.41M to -$153.71M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.